Clinical Trial Update: Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy [EARLY_Phase 1]

View source ↗

Summary

A personalized dendritic cell vaccine is being evaluated in an early-phase trial for high-risk triple-negative breast cancer after neoadjuvant therapy. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Personalized dendritic cell vaccine (Autologous dendritic cell vaccine pulsed with tumor antigens)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Breast Cancer, Triple Negative Breast Cancer | EARLY_Phase 1 | Status: RECRUITING